Today: Today, Supernus Pharmaceuticals Inc. (SUPN) Cut to “Hold” at Zacks Investment Research

Today, Supernus Pharmaceuticals Inc. (SUPN) Cut to “Hold” at Zacks Investment Research

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other equities analysts have also commented on the company. Jefferies Group reissued a “buy” rating and set a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Northland Securities lowered Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target on the stock. in a research report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price target on the stock. in a research report on Monday, July 18th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $25.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 20.69 on Tuesday. The stock’s 50 day moving average is $23.53 and its 200-day moving average is $20.40. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 42.22 and a beta of 1.73. Supernus Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $26.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The business earned $50.40 million during the quarter, compared to analysts’ expectations of $49.67 million. During the same quarter in the previous year, the business earned $0.03 EPS. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. On average, equities research analysts expect that Supernus Pharmaceuticals will post $0.68 earnings per share for the current year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now directly owns 3,616 shares of the company’s stock, valued at approximately $90,400. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.10% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas raised its position in shares of Supernus Pharmaceuticals by 29.6% in the second quarter. Teacher Retirement System of Texas now owns 5,468 shares of the specialty pharmaceutical company’s stock worth $111,000 after buying an additional 1,249 shares during the last quarter. Mason Street Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $138,000. Walleye Trading LLC raised its position in shares of Supernus Pharmaceuticals by 485.5% in the second quarter. Walleye Trading LLC now owns 7,026 shares of the specialty pharmaceutical company’s stock worth $143,000 after buying an additional 5,826 shares during the last quarter. Legal & General Group Plc raised its position in shares of Supernus Pharmaceuticals by 35.9% in the second quarter. Legal & General Group Plc now owns 7,282 shares of the specialty pharmaceutical company’s stock worth $143,000 after buying an additional 1,924 shares during the last quarter. Finally, Advisor Group Inc. acquired a new position in shares of Supernus Pharmaceuticals during the second quarter worth about $147,000. 94.62% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Related posts

Leave a Comment